NBIX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Neurocrine Biosciences published KINECT-PRO findings showing INGREZZA improved quality of life and daily functioning in people with tardive dyskinesiaAug 12, 2026
- Neurocrine Biosciences initiated a Phase 1 clinical study of NBIP-1968, a GLP-1/GIP/glucagon triple agonistAug 7, 2026
- Neurocrine Biosciences initiated a Phase 2 study of crinecerfont in children under 4 with congenital adrenal hyperplasiaJul 2, 2026
- Neurocrine presented new data showing functional and socio-emotional benefits of INGREZZA in patients with tardive dyskinesia and developmental disabilitiesJun 8, 2026
- Neurocrine Biosciences presents real-world data showing functional improvement with INGREZZA in tardive dyskinesia patientsMay 19, 2026